



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/616,409	07/09/2003	Sharlene Adams	I0248.70024US00	9289

7590 12/12/2007  
Maria A. Trevisan  
Wolf, Greenfield & Sacks, P.C.  
600 Atlantic Avenue  
Boston, MA 02210

EXAMINER
----------

FETTEROLF, BRANDON J

ART UNIT	PAPER NUMBER
----------	--------------

1642

MAIL DATE	DELIVERY MODE
-----------	---------------

12/12/2007

PAPER

**Please find below and/or attached an Office communication concerning this application or proceeding.**

The time period for reply, if any, is set in the attached communication.

## Office Action Summary

Application No.

10/616,409

Applicant(s)

ADAMS ET AL.

Examiner

Brandon J. Fetterolf, PhD

Art Unit

1642

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

### Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

### Status

- 1) ☒ Responsive to communication(s) filed on 09 October 2007.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

### Disposition of Claims

- 4) ☒ Claim(s) 1-3, 7-17, 139, 142, 144, 166, 251-260, 338 and 341-348 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 1-3, 7-17, 139, 142, 144, 166, 251-260, 338 and 341-348 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

### Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

### Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some \* c) ☐ None of:
- ☐ Certified copies of the priority documents have been received.
  - ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  - ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- \* See the attached detailed Office action for a list of the certified copies not received.

### Attachment(s)

- ☒ Notice of References Cited (PTO-892)
- ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- ☒ Information Disclosure Statement(s) (PTO/SB/08)  
Paper No(s)/Mail Date 6/29/2007; 11/05/2007.
- ☐ Interview Summary (PTO-413)  
Paper No(s)/Mail Date. \_\_\_\_\_.
- ☐ Notice of Informal Patent Application
- ☐ Other: \_\_\_\_\_.

***Response to the Amendment***

The Amendment filed on 10/09/2007 in response to the previous Non-Final Office Action (04/05/2007) is acknowledged and has been entered.

Claims 1-3, 7-17, 139, 142, 144, 166, 251-260, 338 and 341-348 are currently pending and under consideration.

***Information Disclosure Statement***

The copy of the International Preliminary Examination Report submitted with the Information Disclosure Statement filed on 6/29/2007 is acknowledged. The submission is in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statement is being considered by the examiner. A signed copy of the IDS is attached hereto.

The information disclosure statement filed on 11/05/2007 fails to comply with 37 CFR 1.98(a)(3) because it does not include a concise explanation of the relevance, as it is presently understood by the individual designated in 37 CFR 1.56(c) most knowledgeable about the content of the information, of each patent listed that is not in the English language. It has been placed in the application file, but the information referred to therein has not been considered.

**Rejections Withdrawn:**

The following rejections are withdrawn in view of Applicants amendments to recite that the cancer is refractory to rituximab. In the instant case, the combination cited in prior office action do not teach or suggest administration to a subject having a cancer refractory to rituximab.

The rejection of Claims 1-3, 8-17, 139, 144, 166, 251-260, 338 and 340-347 under 35 U.S.C. 103(a) as being unpatentable over Kaminski et al. (US 6,090,365, 2000, *of record*) as evidenced by Ajay et al. (Proc. Am. Soc. Clin. Oncol. 2001; 20: Abstr 1118, *of record*) in view of Wallner et al. (WO 00/71135, 2000, IDS, *of record*).

The rejection of Claims 1-3, 7-17, 139, 144, 251-260, 338 and 348 under 35 U.S.C. 103(a) as being unpatentable over Anderson et al. (US 5,776,456, 1998, *of record*) as evidenced by Grillo-Lopez et al. (Current Pharmaceutical Biotechnology 2000; 1: 1-9, *of record*) in view of Wallner et al. (WO 00/71135, 2000, IDS, *of record*).

The rejection of Claim 142 under 35 U.S.C. 103(a) as being unpatentable over Kaminski et al. (US 6,090,365, 2000, *of record*) as evidenced by Ajay et al. (Proc. Am. Soc. Clin. Oncol. 2001; 20: Abstr 1118, *of record*) in view of Wallner et al. (WO 00/71135, 2000, IDS, *of record*) and in further view of Buske et al. (European Journal of Cancer 1999; 35: 549-557, *of record*).

Claim 142 is rejected under 35 U.S.C. 103(a) as being unpatentable over Anderson et al. (US 5,776,456, 1998, *of record*) as evidenced by Grillo-Lopez et al. (Current Pharmaceutical Biotechnology 2000; 1: 1-9, *of record*) in view of Wallner et al. (WO 00/71135, 2000, IDS, *of record*) and in further view of Buske et al. (European Journal of Cancer 1999; 35: 549-557, *of record*).

**Rejection Maintained, but amended in view of Applicants amendments:**

Claims 1-3, 7-17, 139, 144, 251-260, 338 and 341-348 remain rejected under 35 U.S.C. 103(a) as being unpatentable over Anderson et al. (US 5,776,456, 1998, *of record*) as evidenced by Grillo-Lopez et al. (Current Pharmaceutical Biotechnology 2000; 1: 1-9, *of record*) in view of Wallner et al. (WO 00/71135, 2000, IDS, *of record*) in further view of Grillo-Lopez et al. (Current Pharmaceutical Biotechnology 2000; 1: 1-9, *of record*).

Anderson et al. in view of Wallner et al. teach, as set forth in the previous office action, a method of treating B-cell lymphoma comprising administering an immunologically effective amount of an anti-CD20 antibody in combination with a boroproline derivative.

The combination of Anderson et al. in view of Wallner et al. does not explicitly teach that the b-cell lymphoma is Non-Hodgkin's lymphoma or a refractory form of Non-Hodgkin's lymphoma to rituximab.

Grillo-Lopez et al. disclose that rituximab has been approved by the FDA for the treatment of relapsed or refractory, CD20 positive, B-cell, low-grade or follicular non-Hodgkin's lymphoma. In addition, Grillo-Lopez et al. disclose that rituximab is safe and well tolerated and has significant

clinical activity in patients with bulky relapsed or refractory LG/F NHL, and in patients who were treated previously with rituximab (page 7, 2<sup>nd</sup> column, 1<sup>st</sup> full paragraph).

It would have been *prima facie* obvious to one of ordinary skill in the art at the time the invention was made to combine the teachings of the references so as to treat Non-Hodgkin's lymphoma or rituximab-refractory non-Hodgkin's lymphoma. One would have been motivated to do so because as taught by Grillo-Lopez et al., rituximab has already been taught in the prior art and approved by the FDA for the treatment of non-Hodgkin's lymphoma and refractory non-Hodgkin's lymphoma; and further, it has significant clinical activity in patients who were treated previously with rituximab. Thus, one of ordinary skill in the art would have a reasonable expectation of success that by administering to a patient suffering from non-Hodgkin's lymphoma or rituximab-refractory non-Hodgkin's lymphoma the combination as taught by Anderson et al. and Wallner et al., one would achieve method of enhancing the efficacy of the existing anti-CD20 therapy for non-Hodgkin's lymphoma or rituximab-refractory non-Hodgkin's lymphoma.

In response to this rejection, Applicants assert that as currently amended, claim 1 is not obvious over Anderson et al., Grillo-Lopez et al., and Wallner et al. because the combination of the cited references does not teach or suggest the elements of currently amended claim 1. Additionally, the cited references alone or in combination do not provide the motivation, let alone the reasonable expectation of success, for one of ordinary skill in the art to treat a subject having a cancer that is refractory to rituximab with an anti-CD20 antibody (such as rituximab).

These arguments have been carefully considered, but are not found persuasive.

In response to Applicants' arguments, the Examiner acknowledges and concedes in part that the combination of Anderson et al. and Wallner et al. does not teach treating a subject having a cancer that is refractory to rituximab with an anti-CD20 antibody. However, the Examiner recognizes that this limitation is taught by Grillo-Lopez et al. as described above. Moreover, the examiner recognizes that references cannot be arbitrarily combined and that there must be some reason why one skilled in the art would be motivated to make the proposed combination of primary and secondary references. *In re Nomiya*, 184 USPQ 607 (CPA 1975). However, there is no requirement that an "express, written motivation to combine must appear in prior art references before a finding of obviousness." See *Ruiz v. A.B. Chance Co.*, 357 F.3d 1270, 1276, 69 USPQ2d 1686, 1690 (Fed. Cir. 2004). For example, motivation to combine prior art references may exist in

the nature of the problem to be solved (Ruiz at 1276, 69 USPQ2d at 1690) or the knowledge of one of ordinary skill in the art (National Steel Car v. Canadian Pacific Railway Ltd., 357 F.3d 1319, 1338, 69 USPQ2d 1641, 1656 (Fed. Cir. 2004)). References are evaluated by what they suggest to one versed in the art, rather than by their specific disclosures. In re Bozek, 163 USPQ 545 (CCPA 1969). In the instant case, as taught by Grillo-Lopez, the knowledge of one of ordinary skill in the art is such that rituximab is recognized as being an effective therapeutic agent for the treatment of non-Hodgkin's lymphoma and refractory non-Hodgkin's lymphoma; and further, has significant clinical activity in patients who were treated previously with rituximab. Assuming arguendo that Applicants are correct with regards to the motivation, the Examiner recognizes that KSR forecloses the argument that a specific teaching, suggestion, or motivation is required to support a finding of obviousness. (See the recent Board decision Ex parte Smith, USPQ2d, slip op. at 20 (Bd. Pat. App. & Interf. June 25, 2007) (citing KSR, 82 USPQ2d at 1369).

#### **New Rejections Necessitated by Amendment:**

##### ***Claim Objections***

Claim 345 is objected to under 37 CFR 1.75(c), as being of improper dependent form for failing to further limit the subject matter of a previous claim. Applicant is required to cancel the claim(s), or amend the claim(s) to place the claim(s) in proper dependent form, or rewrite the claim(s) in independent form. In the instant case, claim 354, which ultimately depends from claim 1, further limits the cancer to a cancer that is refractory to prior treatment comprising a chemotherapeutic agent. However, claim 1 already sets forth that the cancer is refractory to rituximab. Thus, it is unclear whether the tumor is both refractory to rituximab and a chemotherapeutic agent, refractory to only a chemotherapeutic agent, or refractory to only rituximab.

Appropriate correction or clarification is requested.

##### ***Claim Rejections - 35 USC § 112***

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 1-3, 7-17, 139, 142, 144, 166, 251-260, 338 and 341-348 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention. THIS IS A NEW MATTER REJECTION.

Claim 1 has been amended to recite the limitation "...a subject having a cancer refractory to rituximab...." and Applicants submit that support for the amendment can be found on page 59, lines 23-32. For example, page 59, lines 23-32 of the specification recites:

The cancers to be treated may be refractory cancers. A refractory cancer as used herein is a cancer that is resistant to the ordinary standard of care prescribed. These cancers may appear initially responsive to a treatment (and then recur), or they may be completely non-responsive to the treatment. The ordinary standard of care will vary depending upon the cancer type, and the degree of progression in the subject. It may be a chemotherapy, or surgery, or radiation, or a combination thereof. Those of ordinary skill in the art are aware of such standards of care. Subjects being treated according to the invention for a refractory cancer therefore may have already been exposed to another treatment for their cancer. Alternatively, if the cancer is likely to be refractory (e.g., given an analysis of the cancer cells or history of the subject), then the subject may not have already been exposed to another treatment.

Thus, while the specification provides support for cancers refractory to chemotherapy, surgery, or radiation generically, the specification does not appear to provide support for the "species" of cancers refractory to rituximab. Applicant is required to cancel the new matter in the response to this Office Action. Alternatively, applicant is invited to provide sufficient written support for the "limitation" indicated above. See MPEP 714.02 and 2163.06.

### ***Claim Rejections - 35 USC § 103***

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary

skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Claims 1-3, 8-17, 139, 144, 166, 251-260, 338 and 341-347 are rejected under 35 U.S.C. 103(a) as being unpatentable over Kaminski et al. (US 6,090,365, 2000, *of record*) as evidenced by Ajay et al. (Proc. Am. Soc. Clin. Oncol. 2001; 20: Abstr 1118, *of record*) in view of Wallner et al. (WO 00/71135, 2000, IDS, *of record*) and further in view of Horning et al. (Blood 2000; 96 (Suppl. 1): 508a (Abstr. 2184).

Kaminski et al. teach a method of treating a lymphoma in a patient comprising administering a therapeutic dose of a radiolabelled anti-CD20 antibody, wherein the radiometric dose received by the patient is limited to a level that toxicity to bone marrow is not significant and reconstitution of hematopoietic function, by bone marrow transplantation or by other means, is not required (column 5, lines 45-53). With regards to the administration, the patent teaches that the anti-CD20 antibodies can be administered by intravenous injection or intralymphatic injection (column 10, lines 8-24). In addition to treating lymphoma's, the patent also teaches that the method can be applied to the treatment of a variety of leukemia's such as hairy cell leukemia and chronic myeloblastic leukemia's (column 6, lines 10-19). Moreover, the patent teaches that the method of treatment is amendable to the treatment of chronic diseases or diseases that have relapsed after a period of remission (column 6, lines 20-24). Thus, while Kaminski et al. does not specifically teach that the radiolabelled anti-CD20 antibody is tositumomab, the claimed limitation does not appear to result in a manipulative difference when compared to the prior art disclosure because as evidenced by Ajay et al., tositumomab is available through Coulter Pharmaceuticals the assignee of the US 6,090,365 patent. Thus, the claimed antibody appears to be the same as the prior art. The office does not have the facilities and resources to provide the factual evidence needed in order to establish that the product of the prior art does not possess the same material, structural and functional characteristics of the claimed product. In the absence of evidence to the contrary, the burden is on the applicant to prove that the claimed product is different from those taught by the prior art and to establish patentable differences. See *In re Best* 562F.2d 1252, 195 USPQ 430 (CCPA 1977) and *Ex parte Gray* 10 USPQ 2d 1922 (PTO Bd. Pat. App. & Int. 1989).

Kaminski et al. does not explicitly teach a method of enhancing treatment with an anti-CD20 antibody or a fragment thereof in a subject having cancer refractory to rituximab comprising administering an agent of Formula I and an anti-CD20 antibody or a fragment thereof.

Wallner et al teach (abstract) a method of treating a subject with abnormal cell proliferation comprising administering to a subject an effective amount of an agent which appears to be 100% identical to the patentably disclosed agents of Formula's I and II as shown in the specification on page 25, wherein formula II is a cyclic derivative. With regards to the agent of Formula I, the WO document teaches that the agent comprises the formula PR, wherein P is a targeting group which binds to the reactive site of post praline-cleaving enzyme, and R is a reactive group capable of reacting with a functional group in a post proline cleaving enzyme (page 8, lines 12-14). Specifically, the reference teaches (page 2, line 25 to page 3, line 17) that the agent is Val-boro-Pro, wherein the agent may be a racemic mixture of the D/L isomers or may be the all L-isomer. Wallner et al. further teaches (page 43, lines 17+ and Figure 1) that IL-6 levels were increased upon the addition of the agent to Fischer D+ rat and BM stromal cells. Moreover, Wallner et al. disclose (page 22, lines 6-9, 27-28 and page 25, line 23) that the method may further comprise administering the agent in combination with existing therapies for cancer such as the use of monoclonal antibodies and/or localization radiation, wherein the efficacy of the existing therapy is improved. With regards to the administration, the WO document teaches (page 22, lines 11-13 and page 27, lines 28-29) that the agents may be administered prior to, concurrent with, or following the existing therapy. Specifically, the WO document teaches (page 28, lines 24-27) that if the existing cancer is a monoclonal antibody, the treatment can performed at sub-lethal dose. The reference further teaches that the agent may be administered to those patients who may have been immunosuppressed (reduction in lymphoid cells) such as in a patient treated for lymphoma, provided that at the time the treatment the subject has protective or normal levels of hemopoeitic cells (page 20, lines 37-30). In addition to those patients suffering from cancer, Wallner et al. teach that the subject may be HIV negative (page 3, line 27).

Horning et al. teach a method of treating patients having Non-Hodgkins Lymphoma which has progressed or failed to respond to rituximab treatment comprising administering iodine-131 tositumomab. In particular, the reference concludes that iodine-131 tositumomab is a safe and effective treatment strategy for patients who progress after or fail to respond to rituximab.

It would have been *prima facie* obvious to one of ordinary skill in the art at the time the invention was made to combine the teachings of the references so as to treat a cancer refractory to rituximab. One would have been motivated to do so because Horning et al. teaches that radioimmunotherapy using iodine-131 tositumomab is a safe and effective treatment strategy for patients who have progressed after or failed to respond to rituximab. Moreover, the strongest rationale for combining references is a recognition, expressly or impliedly in the prior art or drawn from a convincing line of reasoning based on established scientific principles or legal precedent, that some advantage or expected beneficial result would have been produced by their combination. In *re Sernaker*, 702 F.2d 989, 994-95, 217 USPQ 1, 5-6 (Fed. Cir. 1983). As such, one of skill in the art would have been motivated to do so because Wallner et al. teach that the boroprolone derivatives when used in combination with an existing therapy such as localization radiation (e.g., radioimmunotherapy of cancer) are useful in improving the efficacy of the existing therapies for treating conditions such as cancer. Thus, one of ordinary skill in the art would have reasonably expectation that by administering a compound of formula I or II in combination with the radiolabelled anti-CD20 antibody as taught by Kaminski et al., one would achieve a method of treating cancers refractory to rituximab and enhancing the efficacy of the radiolabelled anti-CD20 antibody.

Moreover, it would have been *prima facie* obvious to one of ordinary skill in the art at the time the invention was made to optimize the administration times and/or routes of administration of the antibody and the compound of Formula I. One would have been motivated to do so because the selection of any order of performing process steps is *prima facie* obvious in the absence of new or unexpected results, see *In re Burhans*, 154 F.2d 690, 69 USPQ 330 (CCPA 1946) or *In re Gibson*, 39 F.2d 975. Thus, one would have a reasonable expectation that the administration of the antibody simultaneously, sequentially or prior to the administration of the second therapeutic agent would result in the treatment of a tumor.

Claim 142 is rejected under 35 U.S.C. 103(a) as being unpatentable over are rejected under 35 U.S.C. 103(a) as being unpatentable over Kaminski et al. (US 6,090,365, 2000, *of record*) as evidenced by Ajay et al. (Proc. Am. Soc. Clin. Oncol. 2001; 20: Abstr 1118, *of record*) in view of Wallner et al. (WO 00/71135, 2000, IDS, *of record*) and in view of Horning et al. (Blood 2000; 96

(Suppl. 1): 508a (Abstr. 2184), as applied above to claims Claims 1-3, 8-17, 139, 144, 166, 251-260, 338 and 341-347, and in further view of Buske et al. (European Journal of Cancer 1999; 35: 549-557, *of record*).

Kaminski et al in view of Wallner et al. and Horning et al. teach a method of enhancing treatment with an anti-CD20 antibody or a fragment thereof in a subject having a lymphoma refractory to rituximab comprising administering a radiolabelled anti-CD20 antibody in combination with a therapeutically effective amount of a boroprolin derivative. In addition to the treatment of lymphoma with a radiolabelled CD20 antibody alone, Kaminski et al. teach the treatment of lymphoma using a combination of anti-CD20 antibodies and radiolabelled antibodies (column 5, lines 54-60).

The combination of Kaminski et al. in view of Wallner et al. and Horning et al. do not explicitly teach that an anti-CD20 antibody conjugated to a toxin.

Buske et al. disclose the emerging concepts monoclonal antibody therapy for B-cell non-Hodgkin's lymphomas. Specifically, the reference teaches that the cytolytic activity of the native Mab can be enhanced by coupling an antibody with a plant or bacterial toxin (page 551, 1<sup>st</sup> column, 2<sup>nd</sup> full paragraph).

It would have been *prima facie* obvious to one of ordinary skill in the art at the time the invention was made to conjugate a bacterial toxin or plant toxin to the anti-CD20 antibody as taught by Kaminski et al. in view of the teachings of Buske et al. One would have been motivated to do so because as taught by Buske et al., conjugation of a plant or bacterial toxin enhances the cytolytic activity of the Mab. Thus, one of ordinary skill in the art would have a reasonable expectation of success that by conjugating a plant or bacterial toxin to an anti-CD20 antibody, one would achieve a method of enhancing the therapeutic effect of the anti-CD20 antibody on B-cell mediated non-Hodgkin's lymphoma refractory to rituximab.

Claim 142 is rejected under 35 U.S.C. 103(a) as being unpatentable over remain rejected under 35 U.S.C. 103(a) as being unpatentable over Anderson et al. (US 5,776,456, 1998, *of record*) as evidenced by Grillo-Lopez et al. (Current Pharmaceutical Biotechnology 2000; 1: 1-9, *of record*) in view of Wallner et al. (WO 00/71135, 2000, IDS, *of record*) and in view of Grillo-Lopez et al. (Current Pharmaceutical Biotechnology 2000; 1: 1-9, *of record*), as applied to Claims 1-3, 7-17, 139,

144, 251-260, 338 and 341-348 above, and in further view of Buske et al. (European Journal of Cancer 1999; 35: 549-557, *of record*).

Anderson et al. in view of Wallner et al. and Grillo-Lopez et al. teach, a method of treating B-cell lymphoma refractory to rituximab comprising administering an immunologically effective amount of an anti-CD20 antibody in combination with a boroproline derivative. Specifically, Anderson et al. teach a method of treating lymphoma comprising administering an immunologically active anti-CD20 antibody, radiolabeled anti-CD20 antibody or a combination of an anti-CD20 antibody and radiolabeled anti-CD20 antibody (abstract).

The combination of Anderson et al. in view of Wallner et al. and Grillo-Lopez et al. does not explicitly teach that the anti-CD20 antibody is conjugated to a toxin such as a plant or bacterial toxin.

Buske et al. disclose the emerging concepts monoclonal antibody therapy for B-cell non-Hodgkin's lymphomas. Specifically, the reference teaches that the cytolytic activity of the native Mab can be enhanced by coupling an antibody with a plant or bacterial toxin (page 551, 1<sup>st</sup> column, 2<sup>nd</sup> full paragraph).

It would have been *prima facie* obvious to one of ordinary skill in the art at the time the invention was made to conjugate a bacterial toxin or plant toxin to the anti-CD20 antibody as taught by Anderson. in view of the teachings of Buske et al. One would have been motivated to do so because as taught by Buske et al., conjugation of a plant or bacterial toxin enhances the cytolytic activity of the Mab. Thus, one of ordinary skill in the art would have a reasonable expectation of success that by conjugating a plant or bacterial toxin to an anti-CD20 antibody, one would achieve a method of enhancing the therapeutic effect of the anti-CD20 antibody on B-cell mediated non-Hodgkin's lymphoma refractory to rituximab.

Therefore, No claims is allowed.

### ***Conclusion***

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).


A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Brandon J. Fetterolf, PhD whose telephone number is (571)-272-2919. The examiner can normally be reached on Monday through Friday from 7:30 to 4:30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Larry Helms can be reached on 571-272-0832. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Brandon J Fetterolf, PhD  
Patent Examiner  
Art Unit 1642



BF